08:45 AM EST, 11/18/2024 (MT Newswires) -- Bausch Health's ( BHC ) Canada subsidiary said Monday Canada's Drug Agency and Quebec's Institut national d'excellence en sante et en services sociaux have given positive reimbursement recommendations for its drug Cabtreo as a treatment for acne vulgaris in patients 12 years of age and older.

The recommendations are a step in the process to have Canada's public drug plans reimburse patients of the medication, the company said.

The drug, a topical treatment made up of clindamycin phosphate, adapalene, and benzoyl peroxide gel, is available by prescription in Canadian pharmacies for treatment of acne vulgaris, the most common type of acne, the company said.